COMBINATION CHEMOTHERAPY FOR OVARIAN CARCINOMA WITH CYCLOPHOSPHAMIDE, ADRIAMYCIN, AND CIS-DICHLORODIAMMINEPLATINUM(II) AFTER FAILURE OF INITIAL CHEMOTHERAPY
- 1 January 1978
- journal article
- research article
- Vol. 62 (7) , 1021-1023
Abstract
Twenty-four patients with stage III or IV ovarian adenocarcinoma who failed prior chemotherapy were treated with cycloposphamide, adriamycin, and cis-dichlorodiammineplatinum(II) every 3 wk. Twelve patients had objective responses and 6 had subjective improvement. The median duration of survival for responders is 9 mo. There were no instances of nephrotoxicity. Fluid management consisted of 1000-2000 ml of i.v. fluid without Lasix or mannitol induced diuresis. Patients responded after having failed radiotherapy or multiple drug chemotherapy, including some who were 70-75 yr of age or were > 50% bedridden. Patients with 1 or 2 drug prior chemotherapy had a higher response rate (10 responses among 17 patients) than those previously treated with 3 or more drugs (2 responses among 7 patients).This publication has 4 references indexed in Scilit:
- Combination chemotherapy with adriamycin andcis-diamminedichloroplatinum in patients with neoplastic diseasesCancer, 1976
- COMBINATION CHEMOTHERAPY WITH ADRIAMYCIN (NSC-123127) AND CYCLOPHOSPHAMIDE (NSC-26271) FOR SOLID TUMORS - PHASE-2 TRIAL1976
- PHASE-2 STUDY OF CIS-DICHLORODIAMMINEPLATINUM(II) (NSC-119875) IN ADVANCED ADENOCARCINOMA OF OVARY1976
- AdriamycinAnnals of Internal Medicine, 1974